NeurAxis’ (NASDAQ:NRXS – Get Free Report) quiet period is set to end on Monday, September 18th. NeurAxis had issued 1,098,667 shares in its public offering on August 9th. The total size of the offering was $6,592,002 based on an initial share price of $6.00. During NeurAxis’ quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
Analyst Ratings Changes
Separately, Westpark Capital assumed coverage on shares of NeurAxis in a research note on Wednesday, August 23rd. They set a “buy” rating for the company.
Get Our Latest Stock Analysis on NeurAxis
NeurAxis Stock Performance
About NeurAxis
NeurAxis, Inc operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics.
Read More
- Five stocks we like better than NeurAxis
- How to Invest in Blockchain Stocks Step by Step
- MarketBeat Week in Review – 9/4 – 9/8
- How to Calculate Inflation Rate
- The Best 5 Small Cap AI Companies to Buy Now
- What is a Special Dividend?
- Miso Robotics Stock: Is an IPO Coming Soon?
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.
